The protective effect of KCNMB1 E65K against hypertension is restricted to blood pressure treatment with beta-blockade

J Hum Hypertens. 2008 Jul;22(7):512-5. doi: 10.1038/jhh.2008.23. Epub 2008 Apr 17.

Abstract

Genetic polymorphisms that influence smooth muscle cell contraction and relaxation may affect the response to anti-hypertensive therapy. Our finding of lower blood pressure (BP) in the setting of treatment for hypertension, particularly with beta-blockade, in Caucasian KCNMB1-E65K-carriers in two community cohorts has implications for personalization of therapy in hypertension.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Blood Pressure / genetics*
  • Cohort Studies
  • Female
  • Gene Frequency / genetics
  • Humans
  • Hypertension / drug therapy*
  • Hypertension / genetics*
  • Large-Conductance Calcium-Activated Potassium Channel beta Subunits / genetics*
  • Male
  • Polymorphism, Genetic / genetics*
  • White People / genetics

Substances

  • Adrenergic beta-Antagonists
  • KCNMB1 protein, human
  • Large-Conductance Calcium-Activated Potassium Channel beta Subunits